Condition: Primary Sjögren's Syndrome (pSS) · Sponsor: Assistance Publique - Hôpitaux de Paris
There are no approved treatments for pSS and the clinical endpoints currently used in clinical trials are inadequate to capture all aspects of the disease that should be evaluated in clinical trials. The newly developed composite endpoint: Sjögren's Tool for Assessing Response to treatment (STAR) will allow a more specific and meaningful assessment of treatment efficacy in pSS. Because of the heterogeneity of the disease and of the central role of the interplay between B- and T-cells in the pathogenesis, it is worth to evaluate combination of conventional synthetic immunomodulatory drugs targeting both B- and T-cells.
This description comes directly from the study's public registry record.
Xavier MARIETTE · 01.45.21.37.51 · xavier.mariette@aphp.fr
Jacques-Eric GOTTENBERG · 03 88 12 79 53 · jacques-eric.gottenberg@chru-strasbourg.fr
Always discuss trial participation with your own doctor first.
| Valérie Devauchelle | Brest, France | Recruiting |
| Eric Hachulla | Lille, France | Recruiting |
| Jacques Morel | Montpellier, France | Recruiting |
| Véronique Le Guern | Paris, France | Recruiting |
| Jacques-Eric Gottenberg | Strasbourg, France | Recruiting |
| Christophe Richez | Talence, France | Recruiting |
| Raphaele Seror | Le Kremlin-Bicêtre, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05113004